CN111465614A - 使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法 - Google Patents

使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法 Download PDF

Info

Publication number
CN111465614A
CN111465614A CN201880046184.1A CN201880046184A CN111465614A CN 111465614 A CN111465614 A CN 111465614A CN 201880046184 A CN201880046184 A CN 201880046184A CN 111465614 A CN111465614 A CN 111465614A
Authority
CN
China
Prior art keywords
siglec
antibody
human
cells
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880046184.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·科纳
B·罗西
N·瓦格曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN111465614A publication Critical patent/CN111465614A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880046184.1A 2017-07-10 2018-07-09 使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法 Pending CN111465614A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530454P 2017-07-10 2017-07-10
US62/530,454 2017-07-10
PCT/EP2018/068532 WO2019011852A1 (en) 2017-07-10 2018-07-09 POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
CN111465614A true CN111465614A (zh) 2020-07-28

Family

ID=62981177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880046184.1A Pending CN111465614A (zh) 2017-07-10 2018-07-09 使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法

Country Status (9)

Country Link
US (2) US11447545B2 (enExample)
EP (1) EP3652207A1 (enExample)
JP (1) JP2020527144A (enExample)
KR (1) KR20200026254A (enExample)
CN (1) CN111465614A (enExample)
AU (1) AU2018298673A1 (enExample)
BR (1) BR112019027353A2 (enExample)
CA (1) CA3066571A1 (enExample)
WO (1) WO2019011852A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CN111263769B (zh) 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
KR20220092918A (ko) 2019-11-04 2022-07-04 알렉터 엘엘씨 Siglec-9 ecd 융합 분자 및 이의 사용 방법
MX2022005717A (es) * 2019-11-14 2022-10-10 Memo Therapeutics Ag Moleculas de anticuerpos anti-siglec-9.
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
EP4257153B1 (en) * 2020-12-04 2025-11-12 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015639A1 (en) * 2008-04-24 2010-01-21 Wisconsin Alumni Research Foundation Methods and Kits to Detect and Monitor Ovarian Cancer and Preeclampsia
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
WO2016041947A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
WO2016062851A1 (en) * 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN108699158A (zh) * 2016-03-08 2018-10-23 依奈特制药公司 Siglec中和抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2022056200A1 (en) * 2020-09-10 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
CN114555123A (zh) * 2019-10-18 2022-05-27 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1307826B1 (it) 1999-12-16 2001-11-19 Dipartimento Di Medicina Speri Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN113929782B (zh) * 2014-09-16 2024-06-21 依奈特制药公司 对淋巴细胞中抑制途径的中和
CA3011092A1 (en) * 2016-01-12 2017-07-20 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
KR20190035863A (ko) * 2016-08-05 2019-04-03 알라코스 인크. 암 치료를 위한 항Siglec-7 항체
CN111263769B (zh) 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015639A1 (en) * 2008-04-24 2010-01-21 Wisconsin Alumni Research Foundation Methods and Kits to Detect and Monitor Ovarian Cancer and Preeclampsia
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
WO2016041947A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
WO2016062851A1 (en) * 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN107073116A (zh) * 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
CN108699158A (zh) * 2016-03-08 2018-10-23 依奈特制药公司 Siglec中和抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN114555123A (zh) * 2019-10-18 2022-05-27 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
WO2022056200A1 (en) * 2020-09-10 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HEINZ LÄUBLI等: "Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer" *
HEINZ LÄUBLI等: "Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer", 《PNAS》 *
MATTHEW S. MACAULEY等: "Siglec regulation of immune cell function in disease" *
MATTHEW S. MACAULEY等: "Siglec regulation of immune cell function in disease", 《NATURE REVIEWS IMMUNOLOGY》 *
王丽: "NKG2A抗体新型免疫疗法可促进机体抗肿瘤能力" *
王丽: "NKG2A抗体新型免疫疗法可促进机体抗肿瘤能力", 《海南医学》 *

Also Published As

Publication number Publication date
US20230085847A1 (en) 2023-03-23
JP2020527144A (ja) 2020-09-03
US11447545B2 (en) 2022-09-20
KR20200026254A (ko) 2020-03-10
CA3066571A1 (en) 2019-01-17
WO2019011852A1 (en) 2019-01-17
EP3652207A1 (en) 2020-05-20
AU2018298673A1 (en) 2019-12-19
US20200369764A1 (en) 2020-11-26
BR112019027353A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
US20230085847A1 (en) Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
CN111263769B (zh) Siglec-9中和性抗体
JP7132981B2 (ja) Ｃｄ７３遮断
JP7270379B2 (ja) Ｓｉｇｌｅｃ中和抗体
EP3191517B1 (en) Cross reactive siglec antibodies
EP3377529B1 (en) Siglec-10 antibodies
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200728